Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
äŒæ¥ã³ãŒãGRAL
äŒç€ŸåGrail Inc
äžå Žæ¥Jun 12, 2024
æé«çµå¶è²¬ä»»è
ãCEOãRagusa (Robert)
åŸæ¥å¡æ°1000
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 12
æ¬ç€Ÿæåšå°1525 O'brien Drive
éœåžMENLO PARK
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94025
é»è©±çªå·18336942553
ãŠã§ããµã€ãhttps://grail.com/
äŒæ¥ã³ãŒãGRAL
äžå Žæ¥Jun 12, 2024
æé«çµå¶è²¬ä»»è
ãCEOãRagusa (Robert)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã